IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $783.33 Average Price Target from Analysts

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $783.3333.

Several equities analysts recently commented on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. BTIG Research lowered their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 over the last three months. Insiders own 0.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. World Investment Advisors grew its stake in IDEXX Laboratories by 126.2% during the fourth quarter. World Investment Advisors now owns 1,902 shares of the company’s stock worth $1,287,000 after buying an additional 1,061 shares during the period. Union Savings Bank purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $2,368,000. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $26,000. Reflection Asset Management acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at $53,000. Finally, BDFS Capital LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at $671,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.2%

Shares of NASDAQ:IDXX opened at $578.51 on Thursday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market cap of $46.00 billion, a price-to-earnings ratio of 44.26, a PEG ratio of 3.50 and a beta of 1.66. The stock’s 50-day moving average price is $642.81 and its two-hundred day moving average price is $664.28. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company earned $2.53 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts forecast that IDEXX Laboratories will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.